Abstract 509P
Background
Novel immunotherapies (IO) show mixed responses, particular in context of brain metastases (BM). We therefore aimed to investigate the density of tumor-associated macrophages (TAM) in primary tumors (PT) and matched BM tissue samples.
Methods
We retrospectively identified patients who received resection of PT and BM between 01/1990 and 10/2022. Immunohistochemical staining and density quantification (positive cells/mm2) of TAMs (CD68+ & CD163+) was performed. Generated heatmaps were analyzed for heterogeneity as quantified by Shannon Entropy.
Results
We included 62 patients (61.3% male, 38.7% female) with matched samples: 46/62 non-small cell lung cancer, 8/62 breast cancer (BC), 8/62 renal cell carcinoma. Median CD163+ TAM density was 733 cells/mm2 (range 105-5110 cells/mm2) in BM and 407 cells/mm2 (range 52-1786 cells/mm2) in PT. Median CD68+ TAM density was 924 cells/mm2 (range 119-5521 cells/mm2) in BM and 744 cells/mm2 (range 99-2164 cells/mm2) in PT. CD163+ TAM density was significantly higher in BM compared to PT over all entities (p<.05). For CD68+ TAM, a significant difference was only observed in BC with higher density in BM than in PT (p=.016). Median difference in CD163+ TAM density between PT and BM was 163 cells/mm2 (range -1258-3602 cells/mm2) and 348 cells/mm2 (range -1390-4390 cells/mm2) in CD68+ TAM. No correlation between TAM density difference and clinical outcome (time to BM and OS from BM) was observed (p>.05). Median entropy for CD163+ TAM in BM was 15.8 (range 1.5-76.2) and 14.3 (range 0.5-45.2) in PT. Concerning CD68+ TAM, median entropy was 19.9 (range 1.8-88.7) in BM and 23.9 (range 1.9-54.9) in PT. A significant difference in entropy was only observed in BC as primary breast cancer CD68+ TAM showed lower entropy indices (p=.02). Median difference in entropy between PT and BM was 3.4 (range -34.8-41.3) in CD163+ TAM and 1.41 (range -34.4-39.9) in CD68+ TAM. No correlation of TAM entropy and clinical outcome (time to BM and OS from BM) was observed (p>.05).
Conclusions
TAM density is significantly higher in BM compared to PT. In BC, higher CD68+ TAM entropy was observed in BM, indicating higher herterogeneity. Further analyses with enlarged cohort and additional immune cell markers are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
M. Mair: Other, Travel Support: Pierre Fabre. G. Heller: Other, Personal, Other: X4 Pharmaceuticals. J.N. Kather: Financial Interests, Personal, Invited Speaker: Fresenius, Eisai, MSD; Financial Interests, Personal, Advisory Board: Owkin, DoMore Diagnostics, Panakeia, London, UK. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer Ingelheim, Bristol Meyers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Meyers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09